Skip to main content

Articles

FDA Approvals, Payers' Guide

Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals

FDA Approvals, Payers' Guide

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure

FDA Approvals, Payers' Guide

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

FDA Approvals, Payers' Guide

Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma

FDA Approvals, Payers' Guide

Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures

FDA Approvals, Payers' Guide

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia

FDA Approvals, Payers' Guide

Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma

FDA Approvals, Payers' Guide

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

FDA Approvals, Payers' Guide

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

FDA Approvals, Payers' Guide

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Page 115 of 244
Results 1141 - 1150 of 2434